Funding of drug treatment of multiple sclerosis should not be delayed.
作者信息
Paty D W
出版信息
BMJ. 1997 Nov 1;315(7116):1160-1. doi: 10.1136/bmj.315.7116.1160b.
Abstract
摘要
相似文献
1
Funding of drug treatment of multiple sclerosis should not be delayed.
BMJ. 1997 Nov 1;315(7116):1160-1. doi: 10.1136/bmj.315.7116.1160b.
2
Rebif offers another option for treating multiple sclerosis.
J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):889-91. doi: 10.1331/108658002762063772.
3
The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Arch Neurol. 2001 Aug;58(8):1297-8. doi: 10.1001/archneur.58.8.1297.
4
Beta interferon and multiple sclerosis: why the fuss?
QJM. 1996 Jan;89(1):1-3. doi: 10.1093/oxfordjournals.qjmed.a030132.
5
Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.
6
Bad decision NICE.
Lancet. 2002 Feb 2;359(9304):447. doi: 10.1016/s0140-6736(02)07582-7.
7
A cost-utility analysis of interferon beta for multiple sclerosis.
Health Technol Assess. 1998;2(4):iii-54.
8
[A short history of beta-interferon therapy of multiple sclerosis].
Med Klin (Munich). 2001 Sep 15;96 Suppl 1:3-9.
9
Shortcomings in pharmacy benefit forecasting--interferon beta products.
J Manag Care Pharm. 2003 Jul-Aug;9(4):373; author reply 374. doi: 10.18553/jmcp.2003.9.4.373.
10
The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Value Health. 2002 Jan-Feb;5(1):1-2. doi: 10.1046/j.1524-4733.2002.51001.x.
Zotero 插件